BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 22021864)

  • 1. Rituximab for refractory granulomatosis with polyangiitis (Wegener's granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations.
    Holle JU; Dubrau C; Herlyn K; Heller M; Ambrosch P; Noelle B; Reinhold-Keller E; Gross WL
    Ann Rheum Dis; 2012 Mar; 71(3):327-33. PubMed ID: 22021864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B-cell depletion with rituximab for refractory head and neck Wegener's granulomatosis: a cohort study.
    Martinez Del Pero M; Chaudhry A; Jones RB; Sivasothy P; Jani P; Jayne D
    Clin Otolaryngol; 2009 Aug; 34(4):328-35. PubMed ID: 19673980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center.
    Cartin-Ceba R; Golbin JM; Keogh KA; Peikert T; Sánchez-Menéndez M; Ytterberg SR; Fervenza FC; Specks U
    Arthritis Rheum; 2012 Nov; 64(11):3770-8. PubMed ID: 22730028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in granulomatosis with polyangiitis: results from a single centre.
    Besada E; Koldingsnes W; Nossent JC
    Rheumatology (Oxford); 2013 Nov; 52(11):2041-7. PubMed ID: 23934313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis (Wegener's). Results of a single-center cohort study on 66 patients.
    Calich AL; Puéchal X; Pugnet G; London J; Terrier B; Charles P; Mouthon L; Guillevin L;
    J Autoimmun; 2014 May; 50():135-41. PubMed ID: 24703438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Off-trial evaluation of the B cell-targeting treatment in the refractory cases of antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: long-term follow-up from a single centre.
    Pullerits R; Ljevak M; Vikgren J; Bokarewa M
    Scand J Immunol; 2012 Oct; 76(4):411-20. PubMed ID: 22823472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis.
    Roubaud-Baudron C; Pagnoux C; Méaux-Ruault N; Grasland A; Zoulim A; LE Guen J; Prud'homme A; Bienvenu B; de Menthon M; Camps S; LE Guern V; Aouba A; Cohen P; Mouthon L; Guillevin L;
    J Rheumatol; 2012 Jan; 39(1):125-30. PubMed ID: 22089465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab.
    Stasi R; Stipa E; Del Poeta G; Amadori S; Newland AC; Provan D
    Rheumatology (Oxford); 2006 Nov; 45(11):1432-6. PubMed ID: 16632482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab with or without a conventional maintenance agent in the treatment of relapsing granulomatosis with polyangiitis (Wegener's): a retrospective single-center study.
    Azar L; Springer J; Langford CA; Hoffman GS
    Arthritis Rheumatol; 2014 Oct; 66(10):2862-70. PubMed ID: 24943239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Orbital masses in granulomatosis with polyangiitis are associated with a refractory course and a high burden of local damage.
    Holle JU; Voigt C; Both M; Holl-Ulrich K; Nölle B; Laudien M; Moosig F; Gross WL
    Rheumatology (Oxford); 2013 May; 52(5):875-82. PubMed ID: 23293138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Severe Wegener's granulomatosis successfully treated with rituximab].
    Semenkova EN; Krivosheev OG; Novikov PI; Osipenko VI; Nosova NR; Parfenova SA; Nikiforova NV; Borodin OO
    Ter Arkh; 2010; 82(6):53-5. PubMed ID: 20731113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Wegener granulomatosis (granulomatosis with polyangiitis): evolving concepts in treatment.
    Lynch JP; Tazelaar H
    Semin Respir Crit Care Med; 2011 Jun; 32(3):274-97. PubMed ID: 21674414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective long-term follow-up of patients with localised Wegener's granulomatosis: does it occur as persistent disease stage?
    Holle JU; Gross WL; Holl-Ulrich K; Ambrosch P; Noelle B; Both M; Csernok E; Moosig F; Schinke S; Reinhold-Keller E
    Ann Rheum Dis; 2010 Nov; 69(11):1934-9. PubMed ID: 20511614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations.
    Aries PM; Hellmich B; Voswinkel J; Both M; Nölle B; Holl-Ulrich K; Lamprecht P; Gross WL
    Ann Rheum Dis; 2006 Jul; 65(7):853-8. PubMed ID: 16269425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of rituximab on refractory Wegener granulomatosis with predominant granulomatous disease.
    Sánchez-Cano D; Callejas-Rubio JL; Ortego-Centeno N
    J Clin Rheumatol; 2008 Apr; 14(2):92-3. PubMed ID: 18391678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis.
    Pagnoux C; Mahr A; Hamidou MA; Boffa JJ; Ruivard M; Ducroix JP; Kyndt X; Lifermann F; Papo T; Lambert M; Le Noach J; Khellaf M; Merrien D; Puéchal X; Vinzio S; Cohen P; Mouthon L; Cordier JF; Guillevin L;
    N Engl J Med; 2008 Dec; 359(26):2790-803. PubMed ID: 19109574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Otolaryngological progression of granulomatosis with polyangiitis after systemic treatment with rituximab.
    Malm IJ; Mener DJ; Kim J; Seo P; Kim YJ
    Otolaryngol Head Neck Surg; 2014 Jan; 150(1):68-72. PubMed ID: 24154746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Experience with rituximab treatment (monoclonal antibodies to B-lymphocyte CD20 receptors) of Wegener's granulomatosis patients with renal impairment].
    Novikov PI; Krivosheev OG; Semenkova EN
    Ter Arkh; 2011; 83(11):70-6. PubMed ID: 22312891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab as Induction Therapy in Eosinophilic Granulomatosis with Polyangiitis Refractory to Conventional Immunosuppressive Treatment: A 36-Month Follow-Up Analysis.
    Thiel J; Troilo A; Salzer U; Schleyer T; Halmschlag K; Rizzi M; Frede N; Venhoff A; Voll RE; Venhoff N
    J Allergy Clin Immunol Pract; 2017; 5(6):1556-1563. PubMed ID: 28916432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lower doses of rituximab in remission induction for refractory granulomatosis with polyangiitis.
    Wawrzycka-Adamczyk K; Zugaj A; Włudarczyk A; Kosałka J; Sznajd J; Bazan-Socha S; Musiał J
    Przegl Lek; 2014; 71(12):663-5. PubMed ID: 25951692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.